Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; LCL 161 (Primary) ; Panobinostat (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2017 Planned End Date changed from 1 Oct 2018 to 12 May 2019.
- 02 Feb 2017 Planned primary completion date changed from 1 Oct 2018 to 12 May 2019.